Stephen C. Glover, CEO of ZyVersa Therapeutics, attends…

Stephen C. Glover, CEO of ZyVersa Therapeutics, attends…

Facebook
Twitter
LinkedIn

  • ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs based on two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for the treatment of kidney disease and Inflammasome ASC Inhibitor IC 100 for the treatment of multiple CNS and other inflammatory diseases
  • Mr. Glover welcomes one-on-one meetings with registered investors to discuss ZyVersa’s technology, pipeline assets and key development milestones

WESTON, Fla., May 11, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. ZVSA or “ZyVersa”)), a specialty clinical-stage biopharmaceutical company developing first-in-class medicines to treat renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman and Chief Executive The Official and President will attend the AGP Virtual Health Conference, taking place May 23-24, 2023.

“We are excited to have the opportunity to schedule virtual one-on-one meetings with registered investors at AGP’s Virtual Healthcare Conference to discuss ZyVersa’s technology, pipeline assets and key development milestones,” said Mr. Glover. “ZyVersa is currently advancing two product candidates: the Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, which is designed to improve renal lipid accumulation, which damages the kidney’s filtration system in patients with glomerular disease, and the investigational Inflammasome ASC Inhibitor IC 100 to block the initiation and maintenance of harmful inflammation associated with numerous inflammatory diseases.

To learn more about ZyVersa and its differentiated product pipeline, please arrange a personal meeting with Mr. Glover by contacting an AGP representative or by emailing AGP Events at agpevents@allianceg.com.

About ZyVersa Therapeutics, Inc.

ZyVersa ZVSA is a clinical-stage, specialty biopharmaceutical company that uses advanced, proprietary technologies to develop first-in-class medicines for patients suffering from renal and inflammatory diseases…



Source story

More to explorer